載入中
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
一般交易時段
US$11.045
−US$0.165 · -1.47%
盤中時間採用ET。市場資料可能有所延遲。
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
日內區間
目前US$11.045
52週區間
目前US$11.045
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
47
合理估值
情緒
55
多空交錯
風險
59
風險偏高
動能
36
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
日內區間
目前US$11.045
52週區間
目前US$11.045
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2.44億 USD | 355萬 USD | 15.1萬 USD | — | 2010萬 USD |
| 銷貨成本 | 150.9萬 USD | — | — | — | — |
| 毛利 | 2.43億 USD | 355萬 USD | 15.1萬 USD | — | 2010萬 USD |
| 研究與開發 | 1.3億 USD | 1.74億 USD | 1.35億 USD | 8726.5萬 USD | 5514.3萬 USD |
| 銷售、一般及管理費用 | 4684.9萬 USD | 4075.4萬 USD | 3483.4萬 USD | 2752.5萬 USD | 2133萬 USD |
| 營業費用 | 1.72億 USD | 2.14億 USD | 1.7億 USD | 1.15億 USD | 7647.3萬 USD |
| 利息收入 | — | — | — | 1000 USD | — |
| 利息支出 | — | — | — | 1000 USD | 4000 USD |
| 折舊和攤銷 | 150.9萬 USD | 122.9萬 USD | 81.5萬 USD | 67.4萬 USD | 37.8萬 USD |
| 營業利益 | 7062.3萬 USD | −2.11億 USD | −1.7億 USD | −1.15億 USD | −5637.3萬 USD |
| 淨利 | 8701.4萬 USD | −1.87億 USD | −1.53億 USD | −1.05億 USD | −5874.4萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$20.33
上漲空間 84.07%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI659.61萬0.00%2.3兆 USD0.03%US$379.69-0.35%
iShares Russell 2000 ETFIWM529.86萬0.01%785.63億 USD0.19%US$275.78-0.69%
Vanguard Extended Market ETFVXF258.45萬0.00%954億 USD0.05%US$231.96-0.66%
iShares Russell 2000 Value ETFIWN195.37萬0.01%139.2億 USD0.24%US$209.07-0.45%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV179.31萬0.01%266.88億 USD0.33%US$37.705-0.24%
iShares Biotechnology ETFIBB154.27萬0.01%104.01億 USD0.44%US$199.42-1.93%
iShares U.S. Small-Cap Equity Factor ETFSMLF119.44萬0.03%41.62億 USD0.15%US$84.195-0.51%
EA Bridgeway Omni Small-Cap Value ETFBSVO119萬0.05%23.74億 USD0.45%US$28.27-0.07%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNU.S. Small Cap Value Portfolio ETF Class SharesDFSViShares Biotechnology ETFIBBiShares U.S. Small-Cap Equity Factor ETFSMLFEA Bridgeway Omni Small-Cap Value ETFBSVOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
